Brought to you by 
Ribozyme closes $48mm private financing
Feb 2003
Executive Summary
Ribozyme Pharmaceuticals (nucleic acid technologies) closed a $48mm private financing of 145.45mm common shares priced at $0.33 each (a 22% premium to market average) and five-year warrants to buy 30mm more common shares at $0.42. Investors (and their post-offering stakes in the company) are Sprout Group (41.8%), Venrock Associates (18.9%), Oxford Bioscience (14.2%), Techno Venture Management (9.2%), and Granite Global Ventures (fund sponsored by Venrock, Singapore Economic Development Board, and U.S. Bancorp Piper Jaffray) (3.7%).
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ribozyme closes $48mm private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice